The American Diabetes Association’s Standard of Care in Diabetes recommends a SGLT-2i and a GLP-1 RA as part of the comprehensive cardiovascular risk reduction and/or glucose-lowering treatment plans in people with T2D who have established atherosclerotic cardiovascular disease or kidney disease [10]. Here, GLP1R is linked to kidney disorder.